CB-03-01 (Cortexolone 17α-propionate)
Acne Vulgaris
Phase IIIRegulatory Review (via Cassiopea)
Key Facts
Indication
Acne Vulgaris
Phase
Phase III
Status
Regulatory Review (via Cassiopea)
Company
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals has successfully transitioned from an R&D-focused venture to a hybrid commercial organization with a mission to develop and commercialize innovative treatments for gastrointestinal diseases, dermatology, and colorectal cancer. Its core achievement is the proprietary MMX® technology, enabling targeted colonic drug delivery, which underpins its flagship products and pipeline. The company's strategy combines direct commercialization in key markets with strategic out-licensing and partnerships to maximize global reach and capital efficiency while advancing a pipeline of novel GI and dermatology assets.
View full company profileTherapeutic Areas
Other Acne Vulgaris Drugs
| Drug | Company | Phase |
|---|---|---|
| Pipeline Program | MatriSys Bioscience | Preclinical |
| AKVANO®-based Acne treatment | Lipidor | Pre-clinical/Phase 1 |
| Acne & Impure Skin | Pelpharma Handels | Commercial |
| GM-503 | Galderma Group | Phase 1 |
| TWYNEO® (tretinoin/BPO) | Sol-Gel Technologies | Commercial |
| SGT-510 | Sol-Gel Technologies | Phase 2 |
| TWYNEO® | Mayne Pharma Group | Marketed |
| TVB-3567 | Sagimet Biosciences | Phase 1 |